Clinical trial · Observational
LOD Before IVF/ICSI in PCOS Patients With High AMH
Laparoscopic Ovarian Drilling Before IVF/ICSI in Polycystic Ovarian Syndrome Patients With High Antimullarian Hormone
NCT03358199CI-TRIAL-00030627completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the effect of performing laparoscopic ovarian drilling (LOD) before proceeding to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) on the cycle outcomes in polycystic ovarian syndrome (PCOS) patients with high antimullerian hormone (AMH) levels
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infertility | — | UNRESOLVED | — |
| Polycystic Ovarian Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LOD | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Study group
- description
- PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
- interventionNames
- Procedure: LOD
- label
- Control group
- description
- PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
Primary outcomes (3)
- measure
- Number of oocytes retrieved
- timeFrame
- 36-38 hours after triggering of oocyte maturation
- description
- Number of collected oocytes during oocyte retrieval
- measure
- Oocyte maturity rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * PCOS women subjected to COS through fixed gonadotropin releasing hormone (GnRH) antagonist protocol with final triggering of oocyte maturation by GnRH agonist (GnRHa) * Elevated serum AMH level (≥ 7 ng/ml) Exclusion Criteria: * Age \< 18 years or \> 35 years * Body mass index (BMI) \< 19 kg/m2 or \> 35 kg/m2 * Use of cabergoline therapy or coasting to minimize the risk of OHSS
References
Publications (0)
Data not yet available
No reference posted for this study.